AIMC Topic: Natalizumab

Clear Filters Showing 1 to 1 of 1 articles

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

Multiple sclerosis (Houndmills, Basingstoke, England)
BACKGROUND: In recent years, a small but increasing number of neurologists choose to extend dose intervals of natalizumab with the aim of reducing the risk of progressive multifocal leukoencephalopathy (PML). This idea is based on the hypothesis that...